896 abstracts found.



Results filter

Literature review of pemetrexed induced pneumonitis

Year:

Session type:

Indrani Bhattacharya1, Suzannah Mawdsley1
1Mount Vernon Cancer Centre, London, UK

CYP26B1 is a prognostic biomarker of colorectal cancer

Year:

Session type:

Gordon Brown1, Beatriz Cash2, Ayham Alnabulsi2, Graeme Murray1
1University of Aberdeen, Aberdeen, UK,2Vertebrate Antibodies, Aberdeen, UK

Trastuzumab infusion reactions in breast cancer: Should we observe after the first dose?

Year:

Session type:

L. J Price1, A. M Brunt1,2
1University Hospital North Staffordshire, Stoke-on-Trent, UK,2Keele University, Stafforshire, UK

Multi-Omics Approach Towards Cancer 4P Medicine

Year:

Session type:

Yong Hou1, Kui Wu1, Shida Zhu1, Xiaofei Ye1, Chang Yu1, Hancheng Zhang1, Guangwu Guo1, Gang Chen1, Xun Xu1, Yingrui Li1, Xiuqing Zhang1, Jian Wang1, Huanming Yang1, Qiang Pan-Hammarström1, Jun Wang1
1BGI, Shenzhen, China

DOUBLE-RESTRICTION ENZYME DIGESTION IMPROVES THE COVERAGE AND ACCURACY OF GENOME-WIDE CPG METHYLATION PROFILING BY REDUCED REPRESENTATION BISULFITE SEQUENCING

Year:

Session type:

Guangliang Yin1, Fei Gao1, Qian Tao2, Yudong Xia1, JunWen Wang1, Lili Li2
1BGI, Shenzhen, China,2The Chinese University of Hong Kong, Hongkong, Hong Kong

Efficacy of eribulin in patients with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status

Year:

Session type:

Chris Twelves1, Javier Cortes2, Linda Vahdat3, Martin Olivo4, Yi He4, Peter A Kaufman5, Ahmad Awada6
1Leeds Institute of Cancer and Pathology and St James's Institute of Oncology, Leeds, UK,2Vall d'Hebron University Hospital, Barcelona, Spain,3Weill Cornell Medical College, New York, USA,4Eisai Inc., Woodcliff Lake, USA,5Norris Cotton Cancer Center and Dartmouth-Hitchcock Medical Center, Lebanon, USA,6Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

The impact of open vs laparoscopic resection for colon cancer on C-reactive protein concentrations as a predictor of postoperative infective complications

Year:

Session type:

Michelle Ramanathan1, Graham MacKay2, Jonathan Platt1, Paul Horgan1, Donald McMillan1
1University of Glasgow, Glasgow, UK,2Glasgow Royal Infirmary, Glasgow, UK

Appropriate or inappropriate use of REMARK guidelines

Year:

Session type:

Cristian Ciria1, Sharon Love1, Corran Roberts1, Milensu Shanyinde2, Doug Altman1
1University of Oxford, Centre for Statistics in Medicine and Oxford Clinical Trials Research Unit, Oxford, UK,2University of Oxford, Primary Care Clinical Trials Unit, Nuffield Department of Primary Care Health Sciences, Oxford, UK

Increasing the potency of organometallic anticancer agents using redox modulators

Year:

Session type:

Isolda Romero-Canelon1, Peter J Sadler1
1University of Warwick, Coventry, UK

ClearCell FX, a marker independent process for enriching Circulating Tumour cells (CTCs) from Melanoma patients blood.

Year:

Session type:

Jackie Pierce1, Jonathan Tugwood1, Karen Morris1, Romina Girotti1, Paul Lorigan2, Alberto Fusi2, Richard Marais1
1Cancer Research UK Manchester Institute, Manchester, UK,2The Christie NHS Foundation Trust, Manchester, UK

A correlation between breast conserving surgery, pathological CR and bioloigcal subtype following neoadjuvant chemotherapy for breast cancer

Year:

Session type:

Kathryn Hawkesford1, Rebecca Roylance1, Sarah Slater1, Virginia Wolstenholme1, Karen Tipples1, Serena Ledwidge1, Jennifer Hu1, Chris Gallagher1
1St Bartholomew's Hospital, London, UK

Development of a functional assay to determine the nucleotide excision repair status of epithelial ovarian cancer

Year:

Session type:

Laura Woodhouse1, Aiste McCormick1, Rachel O'Donnell1, Angelika Kauffmann1, Richard Edmondson2
1Northern Institute for Cancer Research, Newcastle upon Tyne, UK,2Faculty Institute for Cancer Sciences, Manchester, UK

HIV Testing in Oncology: An Audit

Year:

Session type:

Morag Brothwell1, Unell Riley1
1Royal Marsden NHS Foundation Trust, London, UK

Three dimensional (3D) quantitative optical coherence elastography (OCE) for detection and characterisation of prostatic cancer biopsies

Year:

Session type:

Chunhui Li1, Guangying Guan2,3, Ruikang Wang3, Zhihong Huang2, Ghulam Nabi1, Cheng Wei1
1Division of Imaging technology, School of Medicine, University of Dundee, Dundee, Angus, UK,2School of Engineering, Physics and Mathematics, University of Dundee, Dundee, Angus, UK,3Department of Bioengineering, University of Washington, Seattle, Washington, USA

Development and verification of an Ion AmpliSeq™ RNA Lung Fusion Panel: an OncoNetwork collaborative research study

Year:

Session type:

Ian Cree1, Anne Reiman1, José Luis Costa2, José Carlos Machado2, Ludovic Lacroix3, Orla Sheils4, Bastiaan Tops5, Pierre Laurent Puig6, Henriette Kurth7, Aldo Scarpa8, Nicola Normanno9, Harriet Feilotter10, Roy R. Bastien11, Kazuto Nishio12, Christoph Noppen7, Cecily P. Vaughn11, Helene Blons6, Paul Park11, Renato Franco13, Marjolijn Ligtenberg5
1Warwick Medical School, Coventry, UK,2IPATIMUP, Porto, Portugal,3Institut Gustave Roussy, Paris, France,4Trinity College Dublin, Dublin, Ireland,5Radboud university medical center, Nijmegen, The Netherlands,6Université Paris Descartes, Paris, France,7Viollier AG, Basel, Switzerland,8ARC-NET University of Verona, Verona, Italy,9Centro Ricerche Oncologiche Mercogliano, Mercogliano, Italy,10Queen's University, Ontario, Canada,11ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, USA,12Kinki University Faculty of Medicine, Osaka, Japan,13Surgical Pathology, Istituto Nazionale Tumori "Fondazione Pascale", Naples, Italy

Claudin-4 SPECT imaging allows detection of aplastic lesions in a mouse model of breast cancer

Year:

Session type:

Michael Mosley1, James Knight1, Albrecht Neesse2, Patrick Michl2, Veerle Kersemans1, Bart Cornelissen1
1University of Oxford, Oxford, UK,2Philipps University Marburg, Marburg, Germany

Maintenance pemetrexed in Non Small Cell Lung Cancer (NSCLC) – an audit of toxicity and outcomes for 24 patients

Year:

Session type:

Chieh-Yin Huang1, Luke Nolan1, Anne Snow2, Carol Cox2, Christian Ottensmeier1, Judith Cave1
1University Hospital Southampton NHS Foundation Trust, Southampton, UK,2St Mary's Hospital NHS Trust, Isle of Wight, UK

Validation of competitive allele-specific TaqMan® (CAST) PCR assay for AKT1 E17K mutation testing in formalin fixed paraffin embedded tissue

Year:

Session type:

Jessica Whiteley1, Pauline Kirk1, Helen Ambrose1, Jayne Fox0
1AstraZeneca, Macclesfield, UK

Combinatorial treatment of KRAS mutant colorectal cancer with MEK and PI3K pathway inhibitors

Year:

Session type:

Paul Clarke1, Toby Roe1, Paul Workman1
1Cancer Research UK Cancer Therapeutics Unit, Institute of Cancer Research, London, UK

Documentation and prescribing of adjuvant FEC-T in early breast cancer (EBC): Our local experience.

Year:

Session type:

Adam Sharp1, Catherine Harper-Wynne1
1Kent Oncology Centre, Maidstone General Hospital, Hermitage Lane?Maidstone?Kent, ME16 9QQ, UK

Disease recurrence within 12 months of adjuvant chemotherapy for early stage breast cancer

Year:

Session type:

Indrani Bhattacharya1, David Miles1, Mei-Lin Ah-See1, Nihal Shah1, Peter Ostler1, Andreas Makris1
1Mount Vernon Cancer Centre, London, UK

Cross-sectional analysis of cancer vaccination trials registered on the US clinical trials database demonstrates a paucity of immunological trial endpoints and a decline in registration since 2008

Year:

Session type:

Liangjian Lu1, Haixi Yan1, Vijay Shyam-Sundar1, Tobias Janowitz2
1School of Clinical Medicine, University of Cambridge, Cambridge, UK,2Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK

South Tees experience of FOLFIRINOX in locally advanced and metastatic pancreatic cancer

Year:

Session type:

Aung Win Tin1, David Wilson1, Nick Wadd1, Syed Zubair1
1James Cook University Hospital, Middlesbrough, UK

Inter-laboratory pre-validation of the FOCUS4 personalised therapy trial

Year:

Session type:

Susan Richman1, Richard Adams2, Phil Quirke1, Rachel Butler3, Gemma Hemmings1, Helen Roberts3, Michelle James4, Sue Wozniak4, Riya Bathia5, Cheryl Pugh5, Timothy Maughan6, Bharat Jasani7
1Leeds Institute of Cancer and Pathology, Leeds, UK,2Institute of Cancer & Genetics, Cardiff, UK,3Cardiff and Vale Medical Genetics, Cardiff, UK,4Cardiff and Vale Histopathology, Cardiff, UK,5MRC Clinical Trials Unit at UCL, London, UK,6Gray Institute for Radiation Oncology and Biology, Oxford, UK,7Department of Cellular Pathology, Cardiff, UK

Single institution nurse-led Abiraterone treatment clinic : 20 months experience and data analysis

Year:

Session type:

Norma Sidek1,2, Maureen Hamill2
1Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK,2Forth Valley Royal Hospital, Lanarkshire, Scotland, UK

The Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey: a comparison of UK-based clinicians to clinicians in the EU and worldwide regarding adjuvant chemotherapy (AdjCT) treatment decisions for early stage HR+, HER2- breast cancer (BC) patients 

Year:

Session type:

Daniel Rea1, Matti Aapro2, Juan Enrique Bargallo Rocha3, Michele De Laurentiis4, László Landherr5, Barbro Linderholm6,16, Terry Mamounas7, Christos Markopoulos8, Miguel Martin9, Patrick Neven10, Alexander Petrovsky11, Roman Rouzier12, Vincent Smit13, Christer Svedman14, Christoph Thomssen15
1University of Birmingham, Birmingham, UK,2Clinic of Genolier, Genolier, Switzerland,3Instituto Nacional de Cancerologia, Mexico City, Mexico,4National Cancer Institute G. Pascale Foundation, Naples, Italy,5Uzsoki Teaching Hospital, Budapest, Hungary,6Sahlgrenska Academy and University Hospital, Gothenburg, Sweden,7Orlando Health, Orlando, USA,8Athens University Medical School, Athens, Greece,9Hospital General Universitario Gregorio Marañón, Madrid, Spain,10UZ Leuven, Leuven, Belgium,11Russian Cancer Research Center, Moscow, Russia,12Institut Curie-Université Versailles-Saint-Quentin, Paris-Saint-Cloud, France,13Leiden University Medical Center, Leiden, The Netherlands,14Genomic Health, Stockholm, Sweden,SaaleMartin-Luther-University Halle-Wittenberg, Halle,16Karolinska University Hospital, Stockholm, Sweden

From trial to practice: the Northern Ireland Cancer Centre experience with Abiraterone Acetate in men with metastatic castration resistant prostate cancer

Year:

Session type:

Aya El Helali1, Prantik Das1, Suneil Jain1, Darren Mitchell1, Lin Shum1, David Stewart1, Joe O'Sullivan1
1Belfast City Hospital, Belfast, Co. Antrim, UK

An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinones

Year:

Session type:

Burcu Anil3, Elizabeth Blackburn3, Tim Blackburn1, Sarah Cully1, Junfeng Liu2, Karim Bennaceur2, Catherine Drummond2, Jane Endicott2,3, Bernard Golding1, Roger Griffin1, Karen Haggerty1, Xiaohong Lu2, John Lunec2, Herbie Newell2, Charlotte Reville1, Christiane Riedinger3, Anna Watson1, Yan Zhao2, Ian Hardcastle1, Martin Noble2,3
1Newcastle Cancer Centre, School of Chemistry, Newcastle University, Newcastle upon Tyne, UK,2Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK,3Laboratory of Molecular Biophysics, Department of Biochemistry, University of Oxford, Oxford, UK

Tartrate-resistant acid phosphatase as a biomarker of canine mammary tumours

Year:

Session type:

Nicole Poulter1, Michael Day1, Alison Hayman1
1School of Veterinary Science, University of Bristol, Langford, Bristol, UK

Scheduling nab-Paclitaxel with gemcitabine (SIEGE): Randomised phase II trial to investigate two different schedules of nab-Paclitaxel (NP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC)

Year:

Session type:

Pippa Corrie1, Wendi Qian3, Duncan Jodrell1,2, Si-houy Lao-Sirieix3, Pamela Whittaker3, Aarthi Gopinathan2, Anita Chhabra3, Katy Dalchau3, Bristi Basu1,2, Richard Hardy3, Juan Valle4
1Cambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK,2Cancer Research UK - Cambridge Institute, University of Cambridge, Cambridge, UK,3Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK,4The Christie NHS Foundation Trust, Manchester, UK

A feasibility randomised controlled trial looking at the effect on lung cancer diagnosis of giving a Chest X-Ray to smokers aged over 60 with new chest symptoms (ELCID) – feasibility and two-month follow-up data

Year:

Session type:

Richard Neal1, Chris Hurt2, Kirsty Roberts2, Trevor Rogers4, Willie Hamilton3, Rhiannon Tudor Edwards1, Seow Tien Yeo1, Angela Tod6, David Parker5, Emma Thomas Jones2, Kerenza Hood2, Hayley Prout2, Annmarie Nelson2, Allan Barham7, Gareth Griffiths2
1Bangor University, Bangor, UK,2Cardiff University, Cardiff, UK,3Exeter University, Exeter, UK,4Doncaster Royal Infirmary, Doncaster, UK,5Wrexham Maelor Hospital, Wrexham, UK,6Sheffield Hallam University, Sheffield, UK,7Cardiff, Cardiff, UK

Biomarkers for epidermal growth factor receptor (EGFR) inhibitor induced skin toxicity and drug response

Year:

Session type:

Tanusree Paul1, Christian Schumann2, Stefan Rüdiger2, Stefan Boeck3, Volker Heinemann3, Volker Kächele4, Michael Steffens5, Catharina Scholl5, Vivien Hichert5, Thomas Seufferlein4, Julia Carolin Stingl5,6
1Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Ulm, Germany,2Department of Internal Medicine II, University of Ulm, Ulm, Germany,3Department of Internal Medicine III and Comprehensive Cancer Center, Ludwig-Maximilians-University of Munich, Munich, Germany,4Department of Internal Medicine I, University of Ulm, Ulm, Germany,BfArMResearch Division, Federal Institute of Drugs and Medical Devices,6Faculty of Medicine, University of Bonn, Bonn, Germany

Pharmacological inhibition of NRF2 as a novel strategy for overcoming cisplatin resistance in bladder cancer

Year:

Session type:

Richard M. D. Greensmith1, Omar M. S. El-Taji1, Zhi X. Lin3, Ian M. Copple2, Chris E. Goldring2, Syed A. Hussain1
1Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK,2MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK,3School of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China

Recruitment challenges in early phase cancer clinical trials: an analysis from the Drug Development Office, Cancer Research UK

Year:

Session type:

Philip Ross1
1Drug Development Office Cancer Research UK, London, UK

Directing the clinical use of ATR inhibitors

Year:

Session type:

Chris Williamson1, Helen Pemberton1, Rachel Brough1, Richard Elliott1, Christopher Lord1, Alan Ashworth1
1The Institute of Cancer Research, London, UK

Innovative target identification for oral and oropharyngeal cancer therapeutics

Year:

Session type:

Matthew Davidson1, Lynn McGarry1, Daniel James1, Emma Shanks1
1CRUK Beatson Institute, Glasgow, UK

A Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101 in patients with Advanced Malignancies Expressing the Biomarker HR23B

Year:

Session type:

Toby Eyre1, Avinash Gupta1, Nick Coupe1, Ioannis Karydis1, Semira Sheikh3, Graham Collins2, Nick La Thangue3, David Kerr3, Mark Middleton1
1Early Phase Clinical Trials Unit, The Oxford Cancer Centre, Churchill Hospital, Oxford, UK,2Department of Clinical Haematology, The Oxford Cancer Centre, Churchill Hospital, Oxford, UK,3Laboratory of Cancer Biology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford, UK

A Product of Independent beta Probabilities dose Escalation (PIPE) design for dual-agent Phase I trials

Year:

Session type:

Adrian Mander1, Michael Sweeting1
1MRC Biostatistics Unit, Cambridge, UK

Patient and tumour characteristics impacting on lymph node metastases rate (LNMR) in squamous cell carcinoma of the anal canal and margin (SCCA) using data from the NCRI randomised phase III ACT II trial: implications for radiotherapy target volume.

Year:

Session type:

Rob Gynne-Jones1, Helen M Meadows2, Andrew G Renehan3, David Sebag-Montefiore4, Mark Harrison1, Maria Hawkins5, Rebecca Muirhead5, Andre Lopes2, Richard Adams6
1Mount Vernon Centre for Cancer Treatment, Northwood, London, UK,2Cancer Research UK & University College London Cancer Trials Centre, London, UK,3the Christie NHS Foundation Trust,, Manchester, UK,4St James's Institute of Oncology, Leeds, UK,5The Gray Institute of Radiation Oncology and Biology, Oxford, UK,6Cardiff University and Velindre Cancer Centre, Cardiff, UK

Pulmonary Metastasectomy for Colorectal Cancer Metastases in Edinburgh

Year:

Session type:

Archibald Macnair1, Alan Christie1, Ewan Brown1, Hamish Phillips1, Catriona Mclean1, Lesley Dawson1, Sally Clive1, Mark Zahra1
1Edinburgh Cancer Centre, Edinburgh, UK

Cell-free plasma markers of breast cancer in young women and women at high risk

Year:

Session type:

Nuha Almull1, Shona Elshaw1, David Guttery1, Karen Page1, Howard Pringle1, Julian Barwell2, Jacqueline Shaw1
1University of Leicester, Leicester, UK,2University of Leicester, Leicester, UK,3University of Leicester, Leicester, UK,4University of Leicester, Leicester, UK,5University of Leicester, Leicester, UK,6University Hospital of Leicester, Leicester, UK,7University of Leicester, Leicester, UK

Risk factors for emergency presentation with lung and colorectal cancers: a systematic review

Year:

Session type:

Elizabeth Mitchell1, Benjamin Pickwell-Smith2, Una Macleod3
1University of Leeds, Leeds, UK,2Oxford University Hospitals, Oxford, UK,3Hull York Medical School, Hull, UK

Expression of tartrate-resistant acid phosphatase differs in benign and malignant canine melanomas

Year:

Session type:

Rachael Nielsen1, Michael Day1, Alison Hayman1
1School of Veterinary Science, University of Bristol, Langford, Bristol, UK

Evidence around criteria for selecting ovarian cancer patients for BRCA mutation testing – findings from the literature and guidelines review

Year:

Session type:

Diana Eccles1, Encarna Gomez Garcia2, Judith Balmaña3, Birgit Ehlken4, Claudia Schroeder4, Joe Clune5, Ceri Hirst6, Danielle Potter6, Jerzy E Tyczynski6
1Cancer Sciences Academic Unit Faculty of Medicine, University of Southampton and Wessex Regional Genetics Service, Southampton, UK,2Dept of Clinical Genetics, Maastricht UMC+, Maastricht, The Netherlands,3Medical Oncology Dept, Familial Cancer Program, Barcelona, Spain,4IMS Health, Munich, Germany,5Global Product and Portfolio Strategy, AstraZeneca, Melbourn, UK,6Observational Research Center, AstraZeneca, Gaithersburg, MD, USA

A simple mainstreamed, oncogenetic pathway delivers fast, affordable routine BRCA testing for ovarian cancer (OC) patients

Year:

Session type:

Angela George1,2, Helen Hanson1,2, Daniel Riddell1, Frances Smith1, Victoria Cloke1, Martin Gore2,1, Susana Banerjee2,1, Nazneen Rahman1,2
1Institute of Cancer Research, London, UK,2Royal Marsden NHS Foundation Trust, London, UK

Changes in practice for the management of advanced ovarian cancer in a large UK centre

Year:

Session type:

Laura Cossar1, Madhuchanda Chatterjee1, Rosemary Lord1
1Clatterbridge Cancer Centre, Wirral, UK